BioSpace News Archive

Leaders from U.S. Department of Health & Human Services, National Institute on Aging, AARP, Canada’s Centre for Aging+Brain Health Innovation and UsAgainstAlzheimer’s Headline Along with Top Investors and Global Innovators in Aging Technology

Computer Aid, Inc. is pleased to announce it is awarding 10 instructional technology grants, four enrichment program grants, and 52 student scholarships to nonprofit organizations for the 2019-2020 school year.

Dante Labs announced its newest, in-house, sequencing test: GenomeH – the first hybrid whole genome sequencing test to leverage hybrid genome assembly and combine short and long reads sequencing in a single application, for superior coverage, accuracy and precision of the genome.

SIGA Technologies, Inc. announced that the Canadian Department of National Defence has issued an advanced contract award notice, indicating that the CDND intends to purchase up to 15,325 courses of oral TPOXX over four years as specified in the ACAN, with an initial purchase of 2,500 courses.

The California Pharmacists Association is pleased to announce that Lori Kinsey, CMP has joined the organization to lead the CPhA education and conference division, the Center for Learning.

New data for aducanumab strengthens potential for Alzheimer’s therapy in near term, fuels next-generation therapies with more selective binding for toxic species of amyloid beta

Today, the Pharmaceutical Research and Manufacturers of America (PhRMA) named Anne Esposito as senior vice president of federal advocacy, effective January 2020

As radiology professionals gather at the 2019 Radiology Society of North America (RSNA) Annual Meeting, Bayer Radiology is helping to support the expansion of imaging in developing countries through a comprehensive product donation.

The U.S. Food and Drug Administration has approved three applications for first generics of Gilenya (fingolimod) capsules for the treatment of relapsing forms of multiple sclerosis (MS) in adult patients.

EIP Pharma, Inc. (www.eippharma.com), a CNS-focused therapeutics company, today announced that the efficacy and safety data from the REVERSE-SD clinical study were presented at the Clinical Trials in Alzheimer’s Disease (CTAD) meeting in San Diego by the principal investigator of the study, Professor Philip Scheltens of the VU Medical Center in Amsterdam, Netherlands.